Search
Search Results
-
A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?
Purpose of ReviewTo review the factors contributing to underutilization of guideline-directed therapies, identify strategies to alleviate these...
-
Multimorbidity, Polypharmacy, Severe Hypoglycemia, and Glycemic Control in Patients Using Glucose-Lowering Drugs for Type 2 Diabetes: A Retrospective Cohort Study Using Health Insurance Claims in Japan
IntroductionThis study aimed to understand the actual status of multimorbidity and polypharmacy among patients with type 2 diabetes using...
-
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study
Aims/hypothesisWe aimed to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty...
-
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis
Aims/hypothesisEpidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer...
-
Influence of fasting plasma glucose-lowering rate on BNP levels in type 2 diabetes mellitus patients with coronary microcirculation dysfunction
AimThe aim was to analyze the influence of fasting plasma glucose-lowering rate (FPGLR) on plasma BNP levels in type 2 diabetes mellitus (T2DM)...
-
Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
PurposeTo assess the comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging (MRI) in...
-
Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
BackgroundThe escalating prevalence of type 2 diabetes (T2DM) poses an unparalleled economic catastrophe to develo** countries. Cardiovascular...
-
Effect of cognitive behavior therapy (CBT) on lowering of blood glucose levels in gestational diabetes mellitus (GDM) patients: study protocol for a prospective, open-label, randomized controlled trial
BackgroundGestational diabetes mellitus (GDM) is a common perinatal condition. Convincing evidence has shown that hyperglycemia and other chronic...
-
Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project
IntroductionLittle is known about the comparative effects of sodium glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor...
-
Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
AimsPrevious observational studies on glucose-lowering drugs and risk of stroke in type 2 diabetes yielded conflicting results. The aim was to...
-
Cardiovascular Outcome Trials with Glucose-Lowering Drugs
Purpose of ReviewThis review summarizes recent cardiovascular outcome trials (CVOTs) with glucose-lowering drugs.
Recent FindingsThe majority of...
-
Pharmacogenetics of novel glucose-lowering drugs
The aim of this work was to review studies in which genetic variants were assessed with respect to metabolic response to treatment with novel...
-
Medical Therapy for Peripheral Artery Disease
Purpose of ReviewPatients with lower extremity peripheral artery disease (PAD) are at high risk for major adverse cardiovascular events (MACE) and...
-
-
Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
AimTreatment algorithms define lines of glucose lowering medications (GLM) for the management of type 2 diabetes (T2D), but whether therapeutic...
-
Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis
Aims/hypothesisIt is unclear whether glucose per se has a causal impact on risk of stroke and whether glucose-lowering drugs reduce this risk. This...
-
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
IntroductionThere is limited published literature on longitudinal utilization of glucose-lowering agents (GLAs) among patients with type 2 diabetes...
-
Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
BackgroundSodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of a deterioration in heart failure (HF) and mortality in patients with a...
-
Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review
Despite the availability of new treatment classes, glycaemic control in patients with diabetes remains suboptimal globally. The latter is associated...
